KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population

BACKGROUND: KRAS is commonly mutated in non-small cell lung cancer (NSCLC); however, the prognostic and predictive impact of each G12 substitution has not been fully elucidated. The approval of specific G12C inhibitors has modified the idea of KRAS “undruggability”, and although the first-line stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Fancelli, Sara, Caliman, Enrico, Mazzoni, Francesca, Paglialunga, Luca, Gatta Michelet, Marta Rita, Lavacchi, Daniele, Berardi, Rossana, Mentrasti, Giulia, Metro, Giulio, Birocchi, Ilaria, Delmonte, Angelo, Priano, Ilaria, Comin, Camilla Eva, Castiglione, Francesca, Bartoli, Caterina, Voltolini, Luca, Pillozzi, Serena, Antonuzzo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702560/
https://www.ncbi.nlm.nih.gov/pubmed/36452502
http://dx.doi.org/10.3389/fonc.2022.968064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702560/
https://www.ncbi.nlm.nih.gov/pubmed/36452502
http://dx.doi.org/10.3389/fonc.2022.968064

Ejemplares similares